PTGER4 and colitis: EP4-specifc agonists inhibited colitis in wild type mice [31] and EP4 agonists have been developed for treating inflammatory disease in humans, with Rivenprost (ONO-4819CD, AE1-734) showing efficacy in phase II trials in ulcerative colitis [41].